REG - Destiny Pharma PLC - Posting of Annual Report and Notice of AGM

Destiny PharmaAnnouncement

26/04/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230426:nRSZ5895Xa&default-theme=true

RNS Number : 5895X  Destiny Pharma PLC  26 April 2023

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Posting of Annual Report and Accounts, and Notice of AGM

 

 

Brighton, United Kingdom - 26 April 2023 - Destiny Pharma plc (AIM: DEST) a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, announces that
the following documents are now available on the Company's website
at www.destinypharma.com (http://www.destinypharma.com)

 

•    Annual Report and Accounts of the Company for the year ended 31
December 2022

 

•    Notice of the 2023 Annual General Meeting ("AGM") and details for
voting by proxy, which is to be held at 11.00 a.m. on 25 May 2023 at the
offices of finnCap Ltd, One Bartholomew Close, London, EC1A 7BL

 

Printed copies of both documents will be posted to shareholders today.

In order to ensure that shareholders are able to follow the proceedings of the
AGM without attending in person, the Company will provide access online via
the Investor Meet Company platform. However, please note that shareholders
will not be able to vote online at the AGM via the platform and are therefore
requested to submit their votes via proxy, as early as possible. Shareholders
are invited to submit any questions for the Board to consider. Questions can
be pre submitted ahead of the AGM via the Investor Meet Company Platform up
until 9 a.m. the day before the AGM or submitted at any time during the AGM
itself.

Shareholders that wish to attend the AGM remotely should register for the
event in advance by using the following link:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://www.investormeetcompany.com/destiny-pharma-plc/register-investor)

 

For further information, please contact:

 

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

+44 (0) 7931 5000 66
DestinyPharma@optimumcomms.com (mailto:destinypharma@optimumcomms.com)

 

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

MC Services AG
Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

Stern IR - US

Janhavi Mohite

+1-212-362-1200

janhavi.mohite@sternir.com

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has completed a positive Phase 2 clinical trial targeting the prevention of
post-surgical staphylococcal hospital infections including MRSA. It is also
co-developing SPOR-COV(TM), a novel, biotherapeutic product for the prevention
of COVID-19 and other viral respiratory infections and has earlier grant
funded XF drug research projects.

 

For further information on the Company, please visit www.destinypharma.com
(http://www.destinypharma.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAIFMATMTMTBRJ